BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22864947)

  • 1. Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer.
    Jeong JH; Ryu MH; Ryoo BY; Lee SS; Park I; Lee SH; Kim KC; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):523-9. PubMed ID: 22864947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
    N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy.
    Tamura S; Fujitani K; Kimura Y; Tsuji T; Matsuyama J; Iijima S; Imamura H; Inoue K; Kobayashi K; Kurokawa Y; Furukawa H;
    Oncology; 2011; 80(5-6):296-300. PubMed ID: 21778769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Examination of continuity of S-1 adjuvant chemotherapy for gastric cancer patients after gastrectomy].
    Kawabata R; Imamura H; Kishimoto T; Anami S; Yasui Y; Fujino M; Fujii C; Sumida R; Furukawa H
    Gan To Kagaku Ryoho; 2011 May; 38(5):793-5. PubMed ID: 21566439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
    Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Yamada T; Tsuchida K; Hasegawa S; Cho H; Yukawa N; Oshima T; Rino Y; Masuda M; Tsuburaya A
    Ann Surg Oncol; 2013 Jun; 20(6):2000-6. PubMed ID: 23242818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
    Kinoshita T; Nashimoto A; Yamamura Y; Okamura T; Sasako M; Sakamoto J; Kojima H; Hiratsuka M; Arai K; Sairenji M; Fukushima N; Kimura H; Nakajima T
    Gastric Cancer; 2004; 7(2):104-9. PubMed ID: 15224197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Severe bone marrow suppression during adjuvant chemotherapy for gastric cancer by S-1 and its possible relationship to dihydropyrimidine dehydrogenase deficiency].
    Aragane H; Suchi K; Shimomura M; Katano T; Yasui H; Kan K
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):131-3. PubMed ID: 20087047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma.
    Leong CN; Chung HT; Lee KM; Shakespeare TP; Mukherjee RK; Wong LC; Lu JJ; Tey J; Lim R; So JB; Back MF
    Cancer J; 2008; 14(4):269-75. PubMed ID: 18677137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot feasibility study of neoadjuvant chemoradiotherapy with S-1 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases.
    Inoue T; Yachida S; Usuki H; Kimura T; Hagiike M; Okano K; Suzuki Y
    Ann Surg Oncol; 2012 Sep; 19(9):2937-45. PubMed ID: 22466666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
    Namikawa T; Munekage E; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
    Anticancer Res; 2014 Dec; 34(12):7297-301. PubMed ID: 25503163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment.
    Chou WC; Chang CL; Liu KH; Hsu JT; Cheng WH; Hsu HC; Shen WC; Hung YS; Chen JS
    World J Surg Oncol; 2013 Nov; 11():287. PubMed ID: 24180462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
    Wada T; Kunisaki C; Hasegawa S; Takagawa R; Momiyama M; Kosaka T; Makino H; Ono HA; Oshima T; Akiyama H; Endo I
    Anticancer Res; 2013 Apr; 33(4):1747-51. PubMed ID: 23564827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
    Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
    Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors.
    Yeo W; Lam KO; Law AL; Lee CC; Chiang CL; Au KH; Mo FK; So TH; Lam KC; Ng WT; Li L
    Hong Kong Med J; 2017 Feb; 23(1):54-62. PubMed ID: 27966431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
    Tsuchiya T; Nagayasu T; Yamasaki N; Matsumoto K; Miyazaki T; Tagawa T; Nakamura A; Minami H; Taniguchi H; Akamine S; Hisano H; Taniguchi Y
    Clin Lung Cancer; 2012 Nov; 13(6):464-9. PubMed ID: 22424872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.
    Sasako M; Sakuramoto S; Katai H; Kinoshita T; Furukawa H; Yamaguchi T; Nashimoto A; Fujii M; Nakajima T; Ohashi Y
    J Clin Oncol; 2011 Nov; 29(33):4387-93. PubMed ID: 22010012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility study of S-1 for resectable gastric cancer with peritoneal seeding.
    Fujitani K; Tsujinaka T; Hirao M
    Hepatogastroenterology; 2003; 50(51):889-92. PubMed ID: 12828112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Examination of s-1 therapy for adjuvant chemotherapy in patients with advanced gastric cancer].
    Matsui K; Nashimoto A; Yabusaki H; Nakagawa S; Nomura T; Takii Y; Tsuchiya Y; Tanaka O
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):953-7. PubMed ID: 19542714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical study of S-1 for advanced gastric cancer after reduction surgery].
    Inaba Y; Hayashi K; Miura T; Moriya T; Takiguchi M; Isobe H; Watabe S
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1053-7. PubMed ID: 17637541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.